Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,762 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Major Depressive Disorder
Interventions
In SHAPE Lifestyles, Health Club Membership and Education
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Concord, New Hampshire
Conditions
Depression
Interventions
venlafaxine-XR
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

NCT01263197
Conditions
Major Depressive Disorder
Interventions
LY2216684, albuterol, propranolol, placebo for LY2216684, placebo for albuterol, placebo for propranolol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
paliperidone, lithium, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Postpartum Major Depression
Interventions
repeated mood measures and phone depression care management
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Induction of Dreaming With EEG and Anesthesia in Healthy Adults

NCT07198711
Conditions
Healthy Volunteers
Interventions
Propofol - Emergence-from-LOR Protocol, Propofol - Light Sedation Protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stanford, California
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Completed Not applicable Interventional

Triple Chronotherapy in Adolescents

NCT03679962
Conditions
Depressive Disorder, Major, Bipolar Depression, Suicidal Ideation
Interventions
Triple Chronotherapy, Treatment as Usual
Behavioral
Lead sponsor
Billings Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Billings, Montana
Conditions
Major Depressive Disorder
Interventions
FMRI with sham controlled feedback, FMRI with real time feedback
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005
Conditions
Major Depressive Disorder
Interventions
(2R,6R)-Hydroxynorketamine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Recurrent, Obesity, Cardiovascular Diseases, Diabetes, Smoking, Blood Pressure Disorders, Cholesterol, Elevated
Interventions
Peer-delivered and Technology Support Integrated Illness Management and Recovery, Peer support
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Completed Phase 3 Interventional Results available

Study of Pharmacotherapy of Psychotic Depression

NCT00056472
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Olanzapine, Sertraline, placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Worcester, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression

NCT04138680
Conditions
Major Depressive Disorder
Interventions
Active Biofeedback, Sham Biofeedback
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
66
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Imaging of rTMS Treatment for Depression

NCT01829165
Conditions
Major Depressive Disorder, Depression
Interventions
rTMS Treatment, Sham rTMS Treatment
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Early Abuse on Adult Intimate Relationships

NCT01803802
Conditions
Hypoactive Sexual Desire Disorder, Female Sexual Arousal Disorder, Female Orgasmic Disorder, Major Depressive Disorder, Post-traumatic Stress Disorder
Interventions
Expressive writing
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Austin, Texas
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Depression - Major Depressive Disorder
Interventions
transcutaneous spinal direct current stimulation
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Mason, Ohio
Conditions
Asthma, Major Depressive Disorder
Interventions
Non-Interventional
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 70 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Major Depressive Disorder, Depression, Bipolar Disorder, Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions
emotional memory training exercise, memory training exercise
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
Creatine monohydrate, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Major Depressive Disorder
Interventions
Active transcutaneous spinal direct current stimulation, Sham transcutaneous spinal direct current stimulation
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Mason, Ohio